Sustained response to low‐dose rituximab in idiopathic autoimmune hemolytic anemia

Abstract

These data confirm that LD rituximab treatment is effective and induces sustained responses in AIHA, and that a lower dose of the drug is enough to down-regulate autoantibody production.